Open Access

Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer

  • Authors:
    • Jesus Rolando Delgado‑Balderas
    • Hugo Leonid Gallardo‑Blanco
    • Juan  Felipe Yee‑De León
    • Ana Maria Rivas‑Estilla
    • Brenda  Soto‑García
    • Diana Aráiz‑Hernández
    • Raquel Garza‑Guajardo
    • Melissa  Náñez‑Marín
    • David Hernández‑Barajas
    • Aldo Missael García‑Bailón
    • Guillermo  Vízcarra‑Mata
    • Marco Alberto Ocaña‑Munguía
    • Lauro   Salvador Gómez‑Guerra
    • Celia Nohemí Sánchez‑Domínguez
  • View Affiliations

  • Published online on: September 18, 2020     https://doi.org/10.3892/ol.2020.12124
  • Article Number: 261
  • Copyright: © Delgado‑Balderas et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The presence of the genetic variants of the steroid 5‑alpha reductase 2 enzyme, which is encoded by the SRD5A2 gene, has been associated with an increased risk of developing prostate cancer among certain ethnic groups. However, these molecular studies have not been conducted on the Mexican population. The analysis of the genetic variants, rs9282858 and rs523349, was performed in 101 males with prostate cancer and 100 healthy controls classified as males without prostate abnormalities (n=60) and males with benign prostatic hyperplasia (n=40), to identify a probable association with this cancer type in the Northeast Mexican population. An association was identified between prostate cancer and biomass exposure [P=0.012; odds ratio (OR), 2.89; confidence interval (CI)=1.21‑6.88] and tobacco use (P=0.028; OR=1.88; CI=1.07‑3.31), while no association was observed between cancer development and the rs9282858 variant, or between a protective effect and the rs523349 variant. Notably, an association was identified between rs523349 and biomass exposure (P=0.013, OR=3.17; CI=1.23‑8.17 for the G risk allele, and OR=0.32, CI=0.12‑0.81 for the C protective allele) using the dominant genetic model. To the best of our knowledge, the present study was the first of its type to investigate the Mexican population with prostate cancer.
View Figures
View References

Related Articles

Journal Cover

November-2020
Volume 20 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Delgado‑Balderas JR, Gallardo‑Blanco HL, Yee‑De León JF, Rivas‑Estilla AM, Soto‑García B, Aráiz‑Hernández D, Garza‑Guajardo R, Náñez‑Marín M, Hernández‑Barajas D, García‑Bailón AM, García‑Bailón AM, et al: Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer. Oncol Lett 20: 261, 2020
APA
Delgado‑Balderas, J.R., Gallardo‑Blanco, H.L., Yee‑De León, J.F., Rivas‑Estilla, A.M., Soto‑García, B., Aráiz‑Hernández, D. ... Sánchez‑Domínguez, C.N. (2020). Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer. Oncology Letters, 20, 261. https://doi.org/10.3892/ol.2020.12124
MLA
Delgado‑Balderas, J. R., Gallardo‑Blanco, H. L., Yee‑De León, J. F., Rivas‑Estilla, A. M., Soto‑García, B., Aráiz‑Hernández, D., Garza‑Guajardo, R., Náñez‑Marín, M., Hernández‑Barajas, D., García‑Bailón, A. M., Vízcarra‑Mata, G., Ocaña‑Munguía, M. A., Gómez‑Guerra, L. S., Sánchez‑Domínguez, C. N."Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer". Oncology Letters 20.5 (2020): 261.
Chicago
Delgado‑Balderas, J. R., Gallardo‑Blanco, H. L., Yee‑De León, J. F., Rivas‑Estilla, A. M., Soto‑García, B., Aráiz‑Hernández, D., Garza‑Guajardo, R., Náñez‑Marín, M., Hernández‑Barajas, D., García‑Bailón, A. M., Vízcarra‑Mata, G., Ocaña‑Munguía, M. A., Gómez‑Guerra, L. S., Sánchez‑Domínguez, C. N."Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer". Oncology Letters 20, no. 5 (2020): 261. https://doi.org/10.3892/ol.2020.12124